Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials

Journal of Autoimmunity

Volumn 43, Issue , 2013, Pages 60-69

  Samson, Maxime ^a,b   Puéchal, Xavier ^a   Devilliers, Hervé ^b   Ribi, Camillo ^a,c   Cohen, Pascal ^a   Stern, Marc ^d   Pagnoux, Christian ^a   Mouthon, Luc ^a   Guillevin, Loïc ^a  

^a Institut Cochin   (France)

^b HÔPITAL DU BOCAGE   (France)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d Pneumologie   (France)

Author keywords

ANCA; Churg Strauss syndrome; Eosinophilic granulomatosis with polyangiitis; MPO; Relapses

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CHURG STRAUSS SYNDROME; CLINICAL ASSESSMENT TOOL; DEATH; DISEASE FREE SURVIVAL; DRUG PULSE THERAPY; EOSINOPHIL; EOSINOPHILIA; EOSINOPHILIC GRANULOMA; FEMALE; FIVE FACTOR SCORE; FOLLOW UP; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RELAPSE; REMISSION; RISK ASSESSMENT; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; AGED; CHURG-STRAUSS SYNDROME; COHORT STUDIES; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 84878371519     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.03.003     Document Type: Article

References (21)

1. Jennette J.C., Falk R.J., Bacon P.A., Basu N., Cid M.C., Ferrario F., et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013, 65:1-11.
2. Sable-Fourtassou R., Cohen P., Mahr A., Pagnoux C., Mouthon L., Jayne D., et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005, 143:632-638.
3. Sinico R.A., Di Toma L., Maggiore U., Bottero P., Radice A., Tosoni C., et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005, 52:2926-2935.
4. Baldini C., Della Rossa A., Grossi S., Catarsi E., Talarico R., d'Ascanio A., et al. Churg-Strauss syndrome: outcome and long-term follow-up of 38 patients from a single Italian centre. Reumatismo 2009, 61:118-124.
5. Pagnoux C., Guillevin L. Churg-Strauss syndrome: evidence for disease subtypes?. Curr Opin Rheumatol 2010, 22:21-28.
6. Cohen P., Pagnoux C., Mahr A., Arene J.P., Mouthon L., Le Guern V., et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 2007, 57:686-693.
7. Ribi C., Cohen P., Pagnoux C., Mahr A., Arene J.P., Lauque D., et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 2008, 58:586-594.
8. Guillevin L., Lhote F., Gayraud M., Cohen P., Jarrousse B., Lortholary O., et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996, 75:17-28.
9. Guillevin L., Pagnoux C., Seror R., Mahr A., Mouthon L., Le Toumelin P. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011, 90:19-27.
10. Masi A.T., Hunder G.G., Lie J.T., Michel B.A., Bloch D.A., Arend W.P., et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990, 33:1094-1100.
11. Jayne D.R., Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 1997, 72:737-747.
12. Luqmani R.A., Bacon P.A., Moots R.J., Janssen B.A., Pall A., Emery P., et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994, 87:671-678.
13. Hagen E.C., Andrassy K., Chernok E., Daha M.R., Gaskin G., Gross W., et al. The value of indirect immunofluorescence and solid phase techniques for ANCA detection. A report on the first phase of an international cooperative study on the standardization of ANCA assays. EEC/BCR Group for ANCA Assay Standardization. JImmunol Methods 1993, 159:1-16.
14. Hellmich B., Flossmann O., Gross W.L., Bacon P., Cohen-Tervaert J.W., Guillevin L., et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007, 66:605-617.
15. Hiemstra T.F., Walsh M., Mahr A., Savage C.O., de Groot K., Harper L., et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAm Med Assoc 2010, 304:2381-2388.
16. Exley A.R., Bacon P.A., Luqmani R.A., Kitas G.D., Gordon C., Savage C.O., et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997, 40:371-380.
17. Guillevin L., Cohen P., Gayraud M., Lhote F., Jarrousse B., Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999, 78:26-37.
18. Dunogue B., Pagnoux C., Guillevin L. Churg-strauss syndrome: clinical symptoms, complementary investigations, prognosis and outcome, and treatment. Semin Respir Crit Care Med 2011, 32:298-309.
19. Pagnoux C., Quemeneur T., Ninet J., Perrodeau E., Diot E., Kyndt X., et al. Treatment of systemic necrotizing vasculitides in patients >65 years old: results of the multicenter randomized Cortage trial. Arthritis Rheum 2012, 64. S708.
20. Walsh M., Flossmann O., Berden A., Westman K., Hoglund P., Stegeman C., et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012, 64:542-548.
21. Terrier B., Saadoun D., Sene D., Ghillani P., Amoura Z., Deray G., et al. Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides. Ann Rheum Dis 2009, 68:1564-1571.